With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
A mixture of the product of step A (500 mg, 2.5 mmol), methyl 4-(bromomethyl)-3- (trifluoromethyl)benzoate (891 mg, 3.0 mmol) and Et3N(505 mg, 5.0 mmol) in DCM (20 mL) was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (lOOmL), washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica weight: 10 g, eluted with petroleum ether/EA: 10/1) to give the title compound (700 mg, 70%) as oil. 1H MR (400 MHz, CDC13) delta 8.31 (s, 1H), 8.19 (d, J= 8.0 Hz, 1H), 7.95 (d, J= 8.0 Hz, 1H), 4.26-4.16 (m, 1H), 3.95 (s, 3H), 3.86-3.80 (m, 1H), 3.66 (s, 2H), 3.18 – 3.07 (m, 1H), 2.76- 2.68 (m, 1H), 2.58-2.51 (m, 1H), 2.30-2.23 (m, 1H), 2.18 – 2.08 (m, 1H), 1.46 (s, 9H), 1.28- 1.25 (m, 3H)ppm.
169447-70-5, The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; BEIGENE, LTD.; ZHOU, Changyou; ZHANG, Guoliang; WO2014/206344; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics